Antifungal drugs are used commonly for curing fungal infections occurring due to, unclean, unhygienic and damp environment. Invasion of epithelial tissue by microscopic organisms lead to fungal infections. Systemic fungal infections are those caused due to indigestion or inhalation of spores, leading to fungal pneumonia and diseases like candidaisis, meningitis, mucormycosis, etc. are caused by opportunistic fungus. Although majority of the fungal infections and diseases are commonly non-lethal, they are very uncomforting to the host and their common occurrence is responsible for the rising antifungal drugs market. Antifungal drugs work via various mechanisms such as by inhibiting of cell wall formation, cell membrane disruption and cell division.
The major factors that are driving the market are increasing awareness of fungal infections with the growing incidence rate of antifungal infections all over the world, increasing government and corporate funds in the industry. And also the development of public private partnership in the pharmaceutical industry, the rising popularity of over-the-counter antifungal drugs for dermal infections are vastly responsible for the growing antifungal drugs market size. Also, the rising population having weak immune system, in whom the occurrence of fungal infections is much more than average, will drive the market. High prevalence of conventional drugs used for the treatment of fungal infections is significantly restraining the market growth. Cost of drugs and their effectiveness in treatments remain as the challenges for the market
Europe Antifungal Drugs Market is estimated at $3.4 billion in 2018 and projected to grow with CAGR of 3.4% reaching $4.01 billion by 2023. In the following few years, the market is poised to grow hugely with the rising population globally.
The antifungal drugs market is segmented on the basis of drug type into 1. Echinocandins, 2. Azoles, 3. Polyenes, 4. Allylamines and 5. Other Drugs, by type of therapeutic indications into 1. Aspergillosis, 2. Dermatophytosis, 3. Candidiasis and 4. Other therapeutic indications, by applications into 1. Powders, 2. Ointments, 3. Drugs and 4. Pastes. While Azoles (fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole) are systemically acting, Echinocandins (anidulafungin, caspofungin and micafungin) are lipopeptides derived from natural fungal fermentation products and Polyenes (amphotericin B deoxycholate and liposomal amphotericin B. Corifungin) are systemically acting and disrupt eukaryotic cellular membranes. Azoles Antifungal Drugs segment is the largest segment of the market followed by echinocandins.
Based on geography, the Europe antifungal drugs market is sub-segmented into U.K., Spain, Germany, Italy and France. Europe commands second largest share of the global antifungal drugs market next to North America. Germany contributes to the major share of the Europe antifungal drugs market. Growing technological advancements in the Europe region will drive the market.
Alternaria, Pfizer, Novartis, Sanofi-Aventis, Merck & Co., Asperqillus, Kramer Laboratories, Bayer Healthcare, Enzon Pharmaceuticals, Glaxosmithkline Gilead and Abbott Laboratories are some of the major market leaders.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Echinocandins
5.1.2 Azoles
5.1.3 Polyenes
5.1.4 Allylamines
5.1.5 Others
5.2 By Therapeutic Indications
5.2.1 Aspergillosis
5.2.2 Dermatophytosis
5.2.3 Candidiasis
5.2.4 Others
5.3 By Application
5.3.1 Powders
5.3.2 Ointments
5.3.5 Drugs
5.3.4 Pastes
6. Geographical Analysis
6.1 Europe
6.1.1 Introduction
6.1.2 U.K
6.1.3 Spain
6.1.4 Germany
6.1.5 Italy
6.1.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alternaria
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer
8.3 Novartis
8.4 Sanofi-Aventis
8.5 Merck & Co.
8.6 Asperqillus
8.7 Kramer Laboratories
8.8 Bayer Healthcare
8.9 Enzon Pharmaceuticals
8.10 Glaxosmithkline Gilead
8.11 Abbott Laboratories
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
